Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Company Overview - Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs [4][11] - The company is working on late-stage ALXN-1840 for Wilson disease and has several radiopharmaceutical programs in various stages of development [11] Offering Details - Monopar announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share [4] - Additionally, a private placement of pre-funded warrants to purchase 882,761 shares of common stock was priced at$23.789 per warrant [4] - The gross proceeds from both the registered offering and private placement are expected to be $40 million before deducting underwriting discounts and commissions [4][9] - The offering is expected to close on or about December 23, 2024, subject to customary closing conditions [4] Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product, and working capital [9] Management and Underwriters - Piper Sandler & Co. is acting as the sole book-running manager for the offering [5]